Description
This content includes an overview of psychedelic effects investigated by a variety of scientific methods (pharmacodynamics, pharmacokinetics, pharmacogenomics, neuroscience) for several types of psychedelics (e.g., psilocybin, ayahuasca, MDMA, ketamine). The current state of research findings with Psychedelic-Assisted Therapies (PAT) using Ketamine, MDMA and Psilocybin will be detailed. Discussion will cover implications for the future of addiction, trauma, depression, and pain and palliative care treatment. (IPEC: Values and Ethics; Roles and Responsibilities)
Instructor
Dr. Coop received his PhD from the University of Bristol in the area of chemistry of drugs of abuse, followed by a Fogerty post-doctoral fellowship at the National Institutes of Health. He has been a faculty member in the Department of Pharmaceutical Sciences since 1999, serving as chair of the department from 2007-2015. His NIH-funded research area focuses on the design and synthesis of new opioid analgesics with reduced tolerance, and the development of novel antidepressants.
Dr. Leah Sera is an Associate Professor of Pharmacy Practice and Program Director for the Master of Science in Medical Cannabis Science and Therapeutics (MCST) program at the University of Maryland School of Pharmacy. Dr. Sera received her PharmD from the University of Maryland School of Pharmacy and completed two years of post-graduate training, specializing in palliative care. She is a board-certified pharmacotherapy specialist and completed a Master of Arts in Instructional Systems Development at the University of Maryland Baltimore County.
Learning Objectives
Upon the completion of this workshop, participants will be able to:
- Identify and explain the mechanisms of action for different psychedelics, detailing their effects on neurotransmitter systems.
- Summarize findings from at least three recent studies on the therapeutic indications for psychedelics
Bibliography & References
BIBLIOGRAPHY & REFERENCES
Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology volume 48, pages 104–112 (2023) https://www.nature.com/articles/s41386-022-01389-z
Penn A, Dorsen CG, Hope S, Rosa WE. Psychedelic-Assisted Therapy: Emerging Treatments in Mental Health Disorders. The American journal of nursing. 2021;121(6):34-40. doi:10.1097/01.NAJ.0000753464.35523.29
Nichols DE, Walter H. The History of Psychedelics in Psychiatry. Pharmacopsychiatry. 2021;54(4):151-166. doi:10.1055/a-1310-3990:
Target Audience
Social Workers, LCPCs, and Psychologists
We welcome anyone interested in the topic!
Late Fees and Refunds
The base price is $60, which includes CE credit.
Cancellations: **ALL cancellations will be subjected to a $35.00 administration fee.** Cancellations must be received 24 hours in advance prior to the workshop to receive a refund or an account credit.
ADA Accommodations
If you are requesting ADA accommodations, please contact our office via email at least two weeks prior to the workshop date. Requests after that date may not be fulfilled.
Our email address is cpe@ssw.umaryland.edu.
